Philinopside A, a novel marine-derived compound possessing dual anti-angiogenic and anti-tumor effects

International Journal of Cancer

Volumn 114, Issue 6, 2005, Pages 843-853

  Tong, Yunguang ^a,b   Zhang, Xiongwen ^a   Tian, Fang ^a,b   Yi, Yanghua ^c   Xu, Qiangzhi ^c   Li, Ling ^c   Tong, Linjiang ^a   Lin, Liping ^a   Ding, Jian ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Philinopside A; Receptor tyrosine kinase; Tumor angiogenesis

Indexed keywords

4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; FIBROBLAST GROWTH FACTOR RECEPTOR; FLUOROURACIL; GROWTH FACTOR RECEPTOR; PHILINOPSIDE A; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; SAPONIN DERIVATIVE; SEMAXANIB; SURAMIN; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AORTA; APOPTOSIS; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CHORIOALLANTOIS; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; ECHINODERM; EMBRYO; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; IC 50; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SARCOMA; TISSUE CULTURE; TUMOR GROWTH; VASCULAR ENDOTHELIUM;

ANIMALS; AORTA; CELL CULTURE TECHNIQUES; CELL MOVEMENT; CELL PROLIFERATION; CHICK EMBRYO; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; ENDOTHELIAL CELLS; GROWTH SUBSTANCES; MICE; NEOVASCULARIZATION, PATHOLOGIC; RATS; RECEPTOR PROTEIN-TYROSINE KINASES; SAPONINS; SARCOMA; SEA CUCUMBERS;

EID: 17044420935     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20804     Document Type: Article

References (53)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31.
2. Benn SI, Whitsitt JS, Broadley KN, Nanney LB, Perkins D, He L, Patel M, Morgan JR, Swain WF, Davidson JM. Particle-mediated gene transfer with transforming growth factor-beta1 cDNAs enhances wound repair in rat skin. J Clin Invest 1996;98:2894-902.
3. Yamamoto S, Konishi I, Tsuruta Y, Nanbu K, Mandai M, Kuroda H, Matsushita K, Hamid AA, Yura Y, Mori T. Expression of vascular endothelial growth factor (VEGF) during folliculogenesis and corpus luteum formation in the human ovary. Gynecol Endocrinol 1997;11:371-81.
4. Reynolds LP, Redmer DA. Expression of the angiogenic factors, basic fibroblast growth factor and vascular endothelial growth factor, in the ovary. J Anim Sci 1998;76:1671-81.
5. Shawver LK, Lipson KE, Annie T, Fong T, McMahon G, Plowman GD, Strawn LM. Receptor tyrosine kinases as targets for inhibition of angiogenesis. Drug Discov Today 1997;2:50-63.
6. Kaban K, Herbst RS. Angiogenesis as a target for cancer therapy. Hematol Oncol Clin North Am 2002;16:1125-71.
7. Matter A. Tumor angiogenesis as a therapeutic target. Drug Discov Today 2001;6:1005-24.
8. Ferrara N. VEGF: an update on biological and therapeutic aspects. Curr Opin Biotechnol 2000;11:617-24.
9. Hicklin DJ, Witte L, Zhu Z, Liao F, Wu Y, Li Y, Bohlen P. Monoclonal antibody strategies to block angiogenesis. Drug Discov Today 2001;6:517-28.
10. Sun L, McMahon G. Inhibition of tumor angiogenesis by synthetic receptor tyrosine kinase inhibitors. Drug Discov Today 2000;5:344-53.
11. Hamby JM, Showalter HD. Small molecule inhibitors of tumor-promoted angiogenesis, including protein tyrosine kinase inhibitors. Pharmacol Ther 1999;82:169-93.
12. Salgaller ML. Technology evaluation: bevacizumab, Genentech/Roche. Curr Opin Mol Ther 2003;5:657-67.
13. Proksch P, Edrada RA, Ebel R. Drugs from the seas - current status and microbiological implications. Appl Microbiol Biotechnol 2002;59:125-34.
14. Haefner B. Drugs from the deep: marine natural products as drug candidates. Drug Discov Today 2003;8:536-44.
15. Blay JY, Le Cesne A, Verweij J, Scurr M, Seynaeve C, Bonvalot S, Hogendoorn P, Jimeno J, Evrard V, van Glabbeke M, Judson I. A phase II study of ET-743/trabectedin ('Yondelis') for patients with advanced gastrointestinal stromal tumors. Eur J Cancer 2004;40:1327-31.
16. Rubinstein LV, Shoemaker RH, Paull KD, Simon RM, Tosini S, Skehan P, Scudiero DA, Monks A, Boyd MR. Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J Natl Cancer Inst 1990;82:1113-8.
17. Koyama S, Takagi H, Otani A, Suzuma K, Nishimura K, Honda Y. Tranilast inhibits protein kinase C-dependent signalling pathway linked to angiogenic activities and gene expression of retinal microcapillary endothelial cells. Br J Pharmacol 1999;127:537-45.
18. Soeda S, Kozako T, Iwata K, Shimeno H. Oversulfated fucoidan inhibits the basic fibroblast growth factor-induced tube formation by human umbilical vein endothelial cells: its possible mechanism of action. Biochim Biophys Acta 2000;1497:127-34.
19. Nicosia RF, Ottinetti A. Growth of microvessels in serum-free matrix culture of rat aorta. A quantitative assay of angiogenesis in vitro. Lab Invest 1990;63:115-22.
20. Carlini RG, Reyes AA, Rothstein M. Recombinant human erythropoietin stimulates angiogenesis in vitro. Kidney Int 1995;47:740-5.
21. Zaman GJ, Vink PM, van den Doelen AA, Veeneman GH, Theunissen HJ. Tyrosine kinase activity of purified recombinant cytoplasmic domain of platelet-derived growth factor beta-receptor (beta-PDGFR) and discovery of a novel inhibitor of receptor tyrosine kinases. Biochem Pharmacol 1999;57:57-64.
22. Strawn LM, McMahon G, App H, Schreck R, Kuchler WR, Longhi MP, Hui TH, Tang C, Levitzki A, Gazit A, Chen I, Keri G, et al. Flk-1 as a target for tumor growth inhibition. Cancer Res 1996;56:3540-5.
23. Tanaka NG, Sakamoto N, Tohgo A, Nishiyama Y, Ogawa H. Inhibitory effects of anti-angiogenic agents on neovascularization and growth of the chorioallantoic membrane (CAM). The possibility of a new CAM assay for angiogenesis inhibition. Exp Pathol 1986;30:143-50.
24. Pasi A, Qu B, Messiha FS. Classifying cytostatics on the basis of their angiocidal and angiostatic effects. J Med 1993;24:289-300.
25. Yonekura K, Basaki Y, Chikahisa L, Okabe S, Hashimoto A, Miyadera K, Wierzba K, Yamada Y. UFT and its metabolites inhibit the angiogenesis induced by murine renal cell carcinoma, as determined by a dorsal air sac assay in mice. Clin Cancer Res 1999;5:2185-91.
26. Schirner M, Hoffmann J, Menrad A, Schneider MR. Antiangiogenic chemotherapeutic agents: characterization in comparison to their tumor growth inhibition in human renal cell carcinoma models. Clin Cancer Res 1998;4:1331-6.
27. Cao Y. Endogenous angiogenesis inhibitors and their therapeutic implications. Int J Biochem Cell Biol 2001;33:357-69.
28. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 2003;9:677-84.
29. Veikkola T, Alitalo K. VEGFs, receptors and angiogenesis. Semin Cancer Biol 1999;9:211-20.
30. Ferrara N. Vascular endothelial growth factor: molecular and biological aspects. Curr Top Microbiol Immunol 1999;237:1-30.
31. Takahashi A, Sasaki H, Kim SJ, Tobisu K, Kakizoe T, Tsukamoto T, Kumamoto Y, Sugimura T, Terada M. Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res 1994;54:4233-7.
32. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995;55:3964-8.
33. Anan K, Morisaki T, Katano M, Ikubo A, Kitsuki H, Uchiyama A, Kuroki S, Tanaka M, Torisu M. Vascular endothelial growth factor and platelet-derived growth factor are potential angiogenic and metastatic factors in human breast cancer. Surgery 1996;119:333-9.
34. Strawn LM, McMahon G, App H, Schreck R, Kuchler WR, Longhi MP, Hui TH, Tang C, Levitzki A, Gazit A, Chen I, Keri Get al. Flk-1 as a target for tumor growth inhibition. Cancer Res 1996;56:3540-5.
35. Folkman J. Angiogenic zip code. Nat Biotechnol 1999;17:749.
36. Mignatti P, Tsuboi R, Robbins E, Rifkin DB, in vitro angiogenesis on the human amniotic membrane: requirement for basic fibroblast growth factor-induced proteinases. J Cell Biol 1989;108:671-82.
37. Sato Y, Shimada T, Takaki R. Autocrinological role of basic fibroblast growth factor on tube formation of vascular endothelial cells in vitro. Biochem Biophys Res Commun 1991;180:1098-102.
38. Li LY, Safran M, Aviezer D, Bohlen P, Seddon AP, Yayon A. Diminished heparin binding of a basic fibroblast growth factor mutant is associated with reduced receptor binding, mitogenesis, plasminogen activator induction, and in vitro angiogenesis. Biochemistry 1994;33:10999-1007.
39. Dunn IF, Heese O, Black PM. Growth factors in glioma angiogenesis: FGFs, PDGF, EGF, and TGFs. J Neurooncol 2000;50:121-37.
40. Sundberg C, Ljungstrom M, Lindmark G, Gerdin B, Rubin K. Microvascular pericytes express platelet-derived growth factor-beta receptors in human healing wounds and colorectal adenocarcinoma. Am J Pathol 1993;143:1377-88.
41. Sato N, Beitz JG, Kato J, Yamamoto M, Clark JW, Calabresi P, Raymond A, Frackelton AR Jr. Platelet-derived growth factor indirectly stimulates angiogenesis in vitro. Am J Pathol 1993;142:1119-30.
42. Nelson J, Allen WE, Scott WN, Bailie JR, Walker B, McFerran NV, Wilson DJ. Murine epidermal growth factor (EGF) fragment (33-42) inhibits both EGF- and laminin-dependent endothelial cell motility and angiogenesis. Cancer Res 1995;55:3772-6.
43. Fong TA, Shawver LK, Sun L, Tang C, App H, Powell TJ, Kim YH, Schreck R, Wang X, Risau W, Ullrich A, Hirth KP, et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999;59:99-106.
44. Hirata A, Ogawa S, Kometani T, Kuwano T, Naito S, Kuwano M, Ono M, ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res 2002;62:2554-60.
45. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64.
46. Rodriguez-Nieto S, Gonzalez-Iriarte M, Carmona R, Munoz-Chapuli R, Medina MA, Quesada AR. Antiangiogenic activity of aeroplysinin-1, a brominated compound isolated from a marine sponge. FASEB J 2002;16:261-3.
47. Lee RH, Slate DL, Moretti R, Alvi KA, Crews P. Marine sponge polyketide inhibitors of protein tyrosine kinase. Biochem Biophys Res Commun 1992;184:765-72.
48. Wessels M, Konig GM, Wright AD. A new tyrosine kinase inhibitor from the marine brown alga Stylopodium zonale. J Nat Prod 1999;62:927-30.
49. Kakeji Y, Teicher BA. Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents. Invest New Drugs 1997;15:39-48.
50. Te Velde EA, Vogten JM, Gebbink MF, van Gorp JM, Voest EE, Borel RI. Enhanced antitumor efficacy by combining conventional chemotherapy with angiostatin or endostatin in a liver metastasis model. Br J Surg 2002;89:1302-9.
51. Teicher BA, Holden SA, Ara G, Korbut T, Menon K. Comparison of several antiangiogenic regimens alone and with cytotoxic therapies in the Lewis lung carcinoma. Cancer Chemother Pharmacol 1996;38:169-77.
52. Reimer CL, Agata N, Tammam JG, Bamberg M, Dickerson WM, Kamphaus GD, Rook SL, Milhollen M, Fram R, Kalluri R, Kufe D, Kharbanda S. Antineoplastic effects of chemotherapeutic agents are potentiated by NM-3, an inhibitor of angiogenesis. Cancer Res 2002;62:789-95.
53. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:60-5.